Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued to ImprimisRx CA, Inc. (a drug manufacturer) on March 26, 2019, addresses compliance concerns related to drug manufacturing or distribution practices. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office and detailed violation count are not available in this metadata.